Passive anaphylaxis in human lung fragments as a model for testing anti-allergic drugs: its variability and constraints

Int Arch Allergy Appl Immunol. 1983;70(2):138-42. doi: 10.1159/000233311.

Abstract

Histamine release from human lung fragments, passively sensitized and challenged with antigen under standardized experimental conditions, varied between 0 and 41.2% (mean +/- SD 15.6 +/- 10.0%) in 89 experiments. Over 41 lungs, the mean coefficient of variation for release from 10 to 28 tissue replicates was 21.4% (range 7-44%). Sodium cromoglycate and chlorpromazine were both partial antagonists of histamine release producing, at best, 30-40% inhibition. The cromoglycate analogue, bufrolin, showed similar activity. There was considerable variation in the effects of these drugs both within and between experiments. Salbutamol was a more potent and more effective inhibitor of release but it, too, showed variability. Although theoretically a very appropriate model of allergic asthma, passive anaphylaxis in human lung fragments is quantitatively inconsistent and gives only a gross indication of drug efficacy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albuterol / pharmacology
  • Chlorpromazine / pharmacology
  • Cromolyn Sodium / pharmacology
  • Histamine Release / drug effects
  • Humans
  • Hypersensitivity / drug therapy*
  • Hypersensitivity / immunology
  • Lung / drug effects*
  • Lung / immunology
  • Models, Biological*
  • Passive Cutaneous Anaphylaxis*
  • Phenanthrolines / pharmacology
  • Pollen / immunology

Substances

  • Phenanthrolines
  • bufrolin
  • Cromolyn Sodium
  • Albuterol
  • Chlorpromazine